# A Vasoconstriction Study With LEO 90100

> **NCT01946386** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 35 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 90100 Aerosol, foam
- **DRUG:** Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle
- **DRUG:** LEO 90100 Aerosol, foam, vehicle
- **DRUG:** Daivobet® ointment
- **DRUG:** Dermovate® cream
- **DRUG:** Synalar® ointment

## Key facts

- **NCT ID:** NCT01946386
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946386, "A Vasoconstriction Study With LEO 90100". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01946386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*